Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Anticipated CAGR of the Opdivo (nivolumab) Market, and What Factors Will Drive It?

There has been considerable growth in the market size of Opdivo (nivolumab) in the past years. It’s projected to surge from $7,709.49 million in 2024 to $8,335.54 million in 2025, witnessing a compound annual growth rate (CAGR) of 8.1%. This increase during the historical period can be attributed to factors such as growing cancer prevalence, expanded investment in research and development capabilities, increased funding for healthcare facilities, rising instances of non-small lung cancer and an upswing in healthcare spending on capital equipment.

In the coming years, the market size for Opdivo (nivolumab) is projected to witness robust growth, and by 2029, the market value is predicted to reach $11,281.56 million with a compound annual growth rate (CAGR) of 7.9%. Multiple factors contribute to this prospective growth in the forecast period, such as a rise in acceptance of immunotherapy, increased knowledge of immunotherapy and its advantages, an escalation in healthcare investment for capital goods, amplified use of nivolumab for different indications, and a growing inclination towards immunotherapy treatments. Key trends for the forecast period include product enhancement, market growth in new regions, ongoing clinical testing, the increasing emergence of personalized medicine, and progress in cancer research.

How Are the key drivers expanding the growth of the Opdivo (nivolumab) Market?

The rising occurrence of non-small lung cancer is anticipated to accelerate the expansion of the opdivo (nivolumab) market. Non-small cell lung cancer (NSCLC) stands as the most prevalent variant of lung cancer, constituting roughly 85% of all lung cancer instances. Factors contributing to the escalating incidence of non-small cell lung cancer (NSCLC) include smoking, exposure to environmental pollutants, genetic mutations, and a history of cancer in the family. Opdivo functions by inhibiting the PD-1 receptor on immune cells, which bolsters the body’s immune reaction to identify and combat cancer cells. For instance, in 2024, it was reported by the American Cancer Society, a health organization based in the US, that 234,580 fresh lung cancer cases were diagnosed there, with 80% being non-small cell lung cancer (NSCLC). This indicated a rise compared to 2023, when 238,340 individuals were diagnosed with lung cancer. Thus, the rising occurrence of non-small lung cancer is fuelling the expansion of the opdivo (nivolumab) market.

Get Your Free Sample of the Global Opdivo (nivolumab) Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=19914&type=smp

Who Are the Top Companies Contributing to the Growth of the Opdivo (nivolumab) Market?

Major companies operating in the opdivo (nivolumab) market include Bristol-Myers Squibb, Ono Pharmaceutical

How Are Technological Trends Affecting the Growth and Development of the Opdivo (nivolumab) Market?

In the opdivo (nivolumab) market, the prominent trend is the creation of combination therapies to improve treatment effectiveness and broaden its applicability to various forms of cancer. The goal of these combined methods is to circumnavigate resistance mechanisms and offer more extensive treatment alternatives for progressive cancer sufferers. To illustrate, in October 2024, the US-based federal agency, Food and Drug Administration, sanctioned the usage of Opdivo (nivolumab) with platinum-doublet chemotherapy as a treatment before surgery, followed by single-agent nivolumab after surgery, for adults with resectable non-small cell lung cancer. This authorization permits the use of Opdivo in conjunction with platinum-doublet chemotherapy prior to surgery and as a standalone treatment after surgery for patients without identified EGFR or ALK mutations.

Get Instant Access to the Global Opdivo (nivolumab) Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report-

Which Segments of the Opdivo (nivolumab) Market Hold the Most Potential for Future Development?

The opdivo (nivolumab)market covered in this report is segmented –

1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL

2) By Dosage: Injection; Solution; Other Dosages

3) By Demographic: Adult; Pediatric

4) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications

5) By End-User: Hospitals; Clinics; Other End Users

What Are the Key Regions Powering Growth in the Opdivo (nivolumab) Market?

North America was the largest region in the 0pdivo (nivolumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Defines the Scope of the Opdivo (nivolumab) Market?

Opdivo (nivolumab) is a prescription medication that belongs to a class of drugs known as immune checkpoint inhibitors, specifically targeting programmed death-1 (PD-1) receptors. It is a type of immunotherapy used to treat various cancers by enhancing the body’s immune system to detect and destroy cancer cells.

Browse Through More Similar Reports By The Business Research Company:

Protein Assays Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-assays-global-market-report

Therapeutic Proteins Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Kidney Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: